In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Increased Compliance with Tumor Treating Fields (TTFields) is Prognostic for Improved Survival in the Treatment of Glioblastoma: A Subgroup Analysis of the EF-14 Phase III Trial

    Final Number:
    2040

    Authors:
    Steven A. Toms MD MPH FAANS FACS; Zvi Ram

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: Tumor treating fields (TTFields) is an antimitotic therapy comprising low intensity alternating electric currents delivered non-invasively to the tumor region. The EF-14 phase 3 trial [NCT00916409] in newly diagnosed glioblastoma showed that TTFields plus temozolomide (TTFields/TMZ) improved progression-free (PFS) and overall survival (OS) versus TMZ alone; 75% of patients achieved compliance of 75% (=18 hours/day). We analyzed how rates of compliance with TTFields/TMZ correlated with PFS and OS in the EF-14 trial.

    Methods: Compliance was assessed using daily usage data from the NovoTTF-100A (Optune®) computerized log file. Compliance was calculated as %/24-hour period of TTFields delivery. Patients on TTFields/TMZ were segregated into subgroups by % daily compliance: 0 - =30%, 30% - =50%, 50% - =60%, 60% - =70%, 70% - =80%, 80% - =90%, 90% - =100%. A Cox model controlled for sex, extent of resection, MGMT methylation status, age, region, and performance status.

    Results: A threshold value of 50% average daily compliance with TTFields was needed to extend PFS (HR 0.70 95%CI 0.47-1.05) and OS (HR 0.67 95%CI 0.45-0.99) versus TMZ alone. A trend in favor of longer PFS and OS was seen with higher compliance bins (>90% compliance: PFS HR 0.54 95%CI 0.37-0.79; OS HR 0.52 95%CI 0.35-0.79). At compliance >90% median survival was 24.9 months (28.7 months from diagnosis) and 5-year survival was 29.3%. Compliance was independent of gender, extent of resection, MGMT methylation status, age, region and performance status (HR 0.78; p=0.031; for OS at compliance =75% vs <75%).

    Conclusions: A compliance threshold of 50% with TTFields/TMZ treatment correlated with significantly improved outcomes in OS and PFS versus TMZ alone. A trend in favor of longer PFS and OS was seen at higher compliance rates (90%). Increased compliance with TTFields therapy is prognostic for improved survival in glioblastoma.

    Patient Care: This will introduce clinicians to the impact of intensity of treatment to patient survival with tumor treating fields in glioblastoma therapy.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the importance of compliance in athe application of tumor treating fields, 2) Discuss, in small groups,threshold and effective compliance levels, 3) Identify an effective treatment for glioblastoma.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy